Document is current
Any future updates will be listed below
-
Authors
Almoiliqy, Marwan
Li, Peng
Jung, Young-Ho
Zheng, Dorothy
Alshambky, Abeer
Koleilat, Mohamad K. I.
Davies, Michael A. https://orcid.org/0000-0002-0977-0912
Kwong, Lawrence N. https://orcid.org/0000-0001-8370-1432
-
Funding
Funding for this research was provided by:
Melanoma Research Alliance (508743)
Melanoma Research Foundation (717906)
U.S. Department of Health & Human Services | National Institutes of Health (1R01CA251608)
U.S. Department of Health & Human Services | National Institutes of Health (1R01HG011356)
U.S. Department of Health & Human Services | National Institutes of Health (P50CA221703)
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
AIM at Melanoma
American Cancer Society
- License Information
-
More Information
Article History
Received: 26 January 2026
Revised: 16 April 2026
Accepted: 8 May 2026
First Online: 19 May 2026
Competing interests
: MAD has been a consultant to Replimmune, Nurix, Roche/Genentech, Array, Pfizer, Novartis, BMS, GSK, Sanofi-Aventis, Vaccinex, Apexigen, Eisai, Iovance, Merck, and ABM Therapeutics; he is a scientific advisory board member for THERAtRAME; and he has been the PI of research grants to MD Anderson by Roche/Genentech, GSK, Sanofi-Aventis, Merck, Myriad, Oncothyreon, Pfizer, ABM Therapeutics, and LEAD Pharma. The remaining authors declare no competing interests.
